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Conclusions: HNa occurs frequently dunng the acute phase of STEMI and is a strong 
NSTSE (n=47) STSE (n=21) IL6 levels (pg/ml) Independent predictor of increased short-term mortality. 
IL6 gene polymorphism 53% 
G/G (n=31) 43% 
G/C (n=30) 4.3% 
c/c (n=7) 
27% 3.2 * 2.9 
47% 7.2 * 9.9 
24% 13.1 * 15.4 
P value 0.025 (&#61539;2) 0.049 (Kr-Wallis) 
1048-95 C-Reactive Protein Levels as an Early Predictor of 30. 
Day Mortality in Patients With Acute Myocardial 
infarction 
Mahmoud A. Suleiman, Doron Aronson. Michael Kapeliovich. Arthour Kerner. Yishai 
Levy, Haim Hammenan, Rambam Medical Center, Haifa, Israel, Technion Faculty of 
Medicine, Haifa, Israel 
Background: In patients with unstable angina, elevated C-reactive protein (CRP) has 
been shown to predict recurrent coronary events. However, little data is available on the 
prognostic value of CRP in acute myocardial infarction (AMI), and its relation to mea- 
sures of infarct size. 
Methods: CRP was measured within 24-h of symptoms onset in a prospective series of 
348 consecutive patients (mean age 62 + 13 y, men - 76%) with AMI (260 with ST-eleva- 
tion AMI). Echocardiographic examination was performed on day 2 or 3. Thirty-day mor- 
tality was evaluated using Cox proportional-hazards model wtth the following covariates: 
age, gender, prior aspirin use, Killip class, diabetes, peak CK. SBP < 100 mm Hg, 
echocardiographic wall motion score index (WMSI). and repelfusion therapy (primary 
angioplasty or thrombolytic therapy). 
Results: Patients with CRP levels in the upper tertile (>2.2 mg/UL) had higher peak CK 
(1999 t 166 vs 1762 * 116, p = 0.01) and higher echocardiographic wall motion score 
index (1.6 * 0.4 vs 1.5 + 0.4, p < 0.0001). Kaplan-Meier surwal wives indicated that 
patients with CRP levels in the upper tertile were at Increased risk of 30.day mortality 
(Figure). In a Cox’s multivariate analysis, CRP level in the upper tertile was a significant 
and independent predictor of 30-day mortality (Relative Risk = 3.2, 95% Cl 1.2-6.2, p = 
0.007). 
Conclusion: CRP level on admission is a powerful predictor of 30-day mortality in 
patients with AMI independent of infarct size and other traditional predictors of outcome. 
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1048-96 Hyponatremia Is a Powerful Independent Predictor of 
Short-Term Mortality In Patients With Acute ST 
Elevation Myocardial Infarction 
Alexander Goldberq, Haim Hammerman, Sirouch Petcherski, Elena Koifman, Alexander 
Zdorovyak, Michael Kapeliovich, Walter Markiewicz, Doron Aronson. Rambam Medical 
Center, Haifa. Israel 
Background: Hyponatremia (HNa) is recognized as a predictor of adverse outcome in 
hospitalized patients (pts), especially in pts with heart failure. However, little is known 
about the prevalence and prognostic significance of HNa in pts with acute ST-elevation 
myocardial infarctjon (STEMI). 
Methods: We studied 706 consecutive pts (age 62 f 13, 75% male) with STEMI. Plasma 
sodium (Na) was measured on admission and at 24,46, and 72 hours thereafter. go-day 
mortality was evaluated using Cox proportional-hazards model, adjusting for important 
covariates including age, gender, diabetes, Killip class, peak CK, diuretic therapy, reper- 
fusion therapy (thrombolysis or primary angioplasty), ejection fraction, heart rate > 100, 
and svstolic blood oressure < 100 mm Ha on admission. 
Rest&: HNa (N&l35 mmol/L) developed during the first 72-h of hospital stay in 53% 
of Dts. Na decreased to 126.130 mmol/L in 29 ots and to<125 mmollL in 7 ots. Althouoh 
pti receiving diuretics developed HNa more commonly compared to pts who were not 
(64% vs. 46%, p < O.OOOl), the majority of pts (66%) who developed HNa were not 
receiving diuretics. Kaplan-Meyer survival curves indicated that pts who developed HNa 
were at increased risk of go-day mortality (Figure). In a Cox multivariate analysis, HNa 
remained a significant and independent predictor of go-day mortality (RR 3.0, 95% Cl 
1.3-6.5, p = 0.006). 
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1048-97 lschemia Modified Albumin: A New Biomarker of 
Myocardial lschemia for Early Diagnosis of Acute 
Coronary Syndromes 
Michael C. Kontos, Steven Schorer, James D. Kirk, Dana R. Fletcher, Debra L. Morris, 
Virginia Commonwealth University/Medical College of Virginia, Richmond, VA, Mercy 
Healthcare, Sacramento, CA 
Background: Chest paln is one of the most common reasons for emergency department 
(ED) visits in the US, accounting for about 6% of all visits. Identifying the etiology of chest 
pain is challenging and resource-intensive. Although Ml can be diagnosed using sensi- 
tive cardiac injury markers, currently no such marker is available for diagnosing 
ischemia. ED diagnosis is based on the physician’s clinical judgment using findings from 
the history, clinical exam, and diagnostic tests including the ECG and rest myocardial 
perfusion imaging (MPI). However, idenhfication is limited by the sub-optimal sensibvity 
of the ECG. Although MPI has higher sensitivity and negative predictive value (NPV), it is 
not wdely used due to its cost and complexity. lschemla Modified Albumin (IMATM) is 
produced when circulating albumin comes in contact with ischemic myocardium. IMA 
increases with ischemia and is detectable in serum prior to necrosis markers. IMA utility 
and diagnostic accuracy compared to traditional methods for diagnosing myocardial 
ischemia in the ED has not been well described. Methods: We are currently enrolling 
patients (pts)(target = 400) presenting to the ED with acute chest pain. Pts undergo rest 
MPI with either ongoing symptoms or within 1 hour of pain cessation. The ED ECG is 
recorded and serial sampling of IMA before and after rest MPI is performed. Diagnosis of 
ischemia is determined by expert cardiologists blinded to IMA values using all clinical 
data collected at presentation and during routine follow-up. Results: Data from the first 
127 patents was available for analysis; 54 males, 73 females; mean age 52 years (30- 
96). Final diagnosis was 14 positive and 113 negative for &hernia. Sensitivity of IMA 
(cutoff 85 UlmL), ECG, and MPI for ischemia was 71%, 21%, and 69%, respectively. 
NPV of IMA, ECG, and MPI was 90%, 91%, and 96%, respectively. Adding the ECG to 
IMA did not improve sensitivity over IMA alone, but combining results from IMA and MPI 
produced a sensitivity and NPV of 100% Conclusions: These preliminary results sug- 
gest that IMA improves the ability to diagnose myocardial &hernia in pts presenting to 
the ED with acute chest pain. 
1048-98 Early Detection of Myocardial lschemia by a Novel 
Blood-Based Biomarker: The Kinetics of lschemia 
Modified Albumin 
ChrlstoDher deFiliDDi, Samual Yoon, Christian Bounds, Linda Romar. Alexander Ro, 
William Herzog, Lawrence Stafford, Robert H. Christenson, University of Maryland, 
Baltimore, MD 
Background: Quantifying subtle myocardial injury IS now routine, however, early detec- 
tion of myocardial &hernia using serum biomarkers remains elusive. lschemia modified 
albumin@ (IMA) is a promising new blood test for detection of ischemia. We studied IMA 
in the setting of percutaneous coronary intervention (PCI) as a model of known transient 
ischemla. 
Methods: Eleven patients (pts) (age 60+1 I, 7 males) without evidence of ischemia for > 
7 days undergoing single-vessel PCI (6 RCA and 3 LAD) were enrolled. Blood was col- 
lected: pre-PCI after arterial access, <IO minutes post initial balloon inflation (post-lnfl), 
and 2.6, 9, 12. 16 hours (hr) post-PCI. Samples were tested for IMA, troponin T and CK- 
MB. 
Results: All patients had successful PCI, with mean longest and total balloon inflation 
times of 2.5+1 .I and 4.321.9 minutes, respectively. Pre-PCI mean IMA levels (95.4*7.2 
UlmL) increased in IO of 11 pts post-lnfl (104.9ilO.9 UlmL. P<O.OOl versus pre-PCI) 
(Figure). IMA levels post-PC1 at 2 hr (97.6+11.4 U/mL), 6 hr (91.0+12.2 UlmL), 9 hr, 12 hr 
and 16 hr were not significantly different from pre-PCI. Seven patients had ECG or 
echocardiographic evidence of ischemia with PCI, while 2 had post-PC1 injury measured 
by troponin T or CK-MB. 
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Conclusions: The IMA test rapidly detects brief episodes of ischemia during PCI. Ongo- 
ing work will determine the duration and extent of ischemia required to elevate IMA lev- 
els. This test may prove useful to detect patients early in the course of cardiac ischemia. 
suggest that newer blomarkers (CRP and BNP) may be useful to identify women with 
high-risk ACS. 
1048-99 Unexplained Troponin-I Elevations in Patients With 
Increased Left Ventricular Mass 
Shadi M. Hamwi, Arvind K. Sharma, Neil J. Weissman, Steven A. Goldstein, Sue Apple, 
Daniel A. Canes, Ellen E. Pinnow, Joseph Lindsay, Washington Hospital Center, 
Washington, DC 
Background: Elevated Troponin-I (Tn-I) is a known indicator of myocardial infarction. 
However, mild elevations of Tn-I are occasionally noted in the absence of overt myocar- 
dial ischemia. It has been suggested that increased left ventricular mass (LVM) is a 
cause of elevated Tn-I. We sought to further investigate the potential relationship 
between LVM and Tn-I. 
Methods: From a single tertiary hospital ws screened patients presenting for an 
echocardiogram. Patients with acute coronary syndrome, heart failure, ejection fraction 
~55%. pulmonary embolism, pericarditis. creatinine >2 mgldl and sepsis were excluded. 
LVM was calculated by Penn Convention formula using PD-guided M-mode echocardio- 
graphy. Tn-I serum level was measured using a standard immunometric assay (normal 
range O-0.06 ngiml). 
Results: We identified 74 p&ants: 36 with normal LVM and 36 with increased LVM 
(93r18.7 and 164t30.5 g/m’, pcO.001). Mean age was 63.4i15.9 yrs. There were 43 
(56.1%) females and 68 (91.9%) African Americans. Hypertension was less frequent in 
the normal LVM group as compared to the increased LVM group [24 (66.7%) vs 35 
(92.1%), p=O.O09], while other risk factors (age, gender, race, diabetes mellitus, smoking 
and hypercholesterolemia) were not significantly different. There was no ECG evidence 
of myocardial ischemia in any patient. No patient with a normal LVM had elevated Tn-I, 
while 9 patients (23.7%) with Increased LVM had Tn-I elevation (median 0, range O-0.06 
vs median 0.02, range O-O.25 ng/ml, p=O.O4). Of the 21 patients with increased LVM 
>I50 g/m*, 8 (38.1%) had elevated Tn-I. 
Conclusion: Patients with Increased LVM have significantly increased Tn-I levels as 
compared to patients with normal LVM. There appears to be a relationship between the 
extent of LVM increase and elevation of Tn-I. Therefore, mild elevation of Tn-I in the 
presence of left ventricular hypertrophy may be a normal finding. 
1048-114 Gender Differences in Cardiac Biomarkers in Patients 
With Unstable Angina and Non-ST Elevation Myocardial 
Infarction in TACTICS-TIM1 18 
Steohen D. Wiviott, Christopher P. Cannon, David A. Morrow, Marc S. Sabatine, Sabina 
A. Murphy, Nadir Rafai, Peter M. DiBattiste, C. Michael Gibson, Carolyn H. McCabe, 
Eugene Braunwald. Brigham and Women’s Hospital, Boston, MA 
Background: Diagnosis of coronary artery disease in women is more difficult due to 
lower diagnostic accuracy of non-invasive testing and electrocardiography. We sought to 
examine the relationship between gender and cardiac biomarkers in patients presenting 
with acute coronary syndromes (ACS). 
Methods: In TACTICS-TIMI 18 and TIMI II, biomarker samples were drawn at baseline 
and analyzed in the TIMI core laboratory. We examined the relationship between gender 
and levels of presenting biomarkers, and the relatlonship between gender, “positive’ 
biomarkers and outcome. 
Results: Among 1846 patients from TIMI 16. 34% were women. Mean levels of Tnl and 
TnT were lower in women (Tnl: 4.1 vs 6.3 nglml for men, p<.OOOl; TnT: 0.26 vs .39 ngl 
ml, p=O.Ol), whereas levels of hs-CRP and BNP were higher (CRP: 1.6 vs 1.3 mg/dl, 
pcO.05; BNP 66 vs 46 pglml, pc 0.0001). When examined using accepted cut points, 
fewer women had elevated troponins, while more had elevated CRP or BNP (Figure, 
p<.Ol for each). Presence of ST segment deviation, and TIMI risk scores were not signif- 
icantly different between genders. This pattern of biomarkers was confirmed in TIMI Il. 
Six-month mortality among patients with each positlve biomarker was similar for men and 
women 
Conclusions: In patients with non-ST elevation ACS, there was a different pattern oi 
biomarkers on admission between men and women. If prospectively validated, our data 
1048-115 Early Decreased Interleukin-6 but Persistently Elevated 
von Willebrand Factor During Long-Term Dalteparin 
Treatment in Unstable Coronary Artery Disease 
Jonas Oldaren, Lars Wall&in, Agneta Siegbahn. University Hospital, Uppsala, Sweden 
Background: Unstable coronary artery disease (CAD) is associated with an acute-phase 
response. Interleukin-6 (11-6) is present in the atherosclerotic plaque and IS secreted by 
both endothelial cells, smooth muscle cells and macrophages. van Willabrand factor 
(vWF). stored in endothelial cells and platelet granules, is rapidly released at the local 
site of the injured coronary artery and has a major role in platelet adhesion to exposed 
subendothelium. 
Methods: II-6 and vWF antigen were analyzed in serial samples from 556 out of the 2267 
patients with unstable CAD in the Scandinavian multicenter study FRISC II. All patients 
were treated with subcutaneous dalteparin 120 IU/kg twice dally for 5-7 days and then 
randomized to placebo (n=266) or long-term treatment with weight-adjusted doses of 
dalteparin (5000 or 7500 IU) twice daily (n=272) for three months. Follow-up was 3 
months after cessation of treatment. 
Results: See table. Data are medians and Mann-Whitney tests. 
Conclusion: The initially high levels of II-6 were early decreased, wth no differences 
between the groups in II-6 levels during long-term dalteparinlplacebo treatment. Patients 
randomized to placebo had a significant decrease in vWF levels after cessation of in-hos- 
pital dalteparin treatment. However, patients randomized to long-term dalteparin treat- 
ment had significantly higher vWF levels up to 3 months, followed by a significant 
decrease. This might contribute to the lack of efficacy by lopg-term dalteparin treatment 
in unstable CAD. 
11-6, rig/L P vWF, % P 
In-hospital: dalteparin 120 U/kg dalteparin 120 U/kg 
randomization 4.8 5.6 0.03 152 154 0.7 
2 days 3.7 4.3 0.04 161 162 0.7 
Long-term: dalteparin placebo dalteparin placebo 
4-7 weeks 2.4 2.2 0.3 162 137 <O.OOl 
3 months 2.4 2.1 0.2 162 136 CO.001 
Follow-up 6 mo 2.2 2.1 0.6 142 134 0.01 
1048-116 A Deadly Combination: Elevated Troponin I and 
Peripheral White Blood Cell Count Imply Poor 
Prognosis in Patients With Suspected Myocardial Injury 
Ali F. Sonel Chester B. Good, Mary E. Kelley, Lauren Wall, Jeffrey Whittle, Michael J. 
Fine, VA Pittsburgh Healthcare System, Center for Health Equity Research and 
Promotion, Pittsburgh, PA, University of Pittsburgh, Cardiovascular Institute, Pittsburgh, 
PA 
Background: Abnormal troponin values predict short and long-term cardiac events in 
patients with non-ST-segment elevation Ml (NSTEMI) and unstable angina (UA). White 
blood cell (WBC) elevations have also been reported to predict adverse events in the 
same population. The additive value of WBC over troponin levels is unknown. 
Methods: To determine the additive value of WBC counts to troponin I (Tnl). we pro- 
spectively studied 365 patients without ST-elevation, admitted with suspicion of Ml. Clini- 
cal information was determined by chart review. Patients were followed for 30.day 
endpoint of death or new MI. Elevated WBC was defined as >I 1 Wmn?. Manufacturer 
cut-off was used for abnormal Tnl. Univariate predictors of events were entered into a 
multivariable model. 
Results: Mean age was 66 +/- Il. During follow up events occurred in 36 patients 
(10.4%). Patients with events had hlgher mean WBC count compared to event free 
patients (12 +I- 6 vs. 9 +/-7, p=O.O15). Event rates were 4% wth both normal Trill and 
WBC, 14% with one being abnormal and 25% if both were abnormal (p<O.Ol). Significant 
univarlate predictors of events were elevated Tnl, elevated CKMB, elevated WBC, hemo- 
dynamic instability, pulmonary edema, age >64, ST-segment changes, and Canadian 
Cardiovascular Class III-IV at presentation 
